TYRA — Tyra Biosciences, Inc.

Is TYRA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Tyra Biosciences, Inc. (TYRA) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $19.57. The rating moved from Neutral to Strong Oversold on November 12, 2026.

See all oversold Healthcare stocks →

AI analysis

Tyra Biosciences is an early‑stage biopharma whose equity value is driven primarily by pipeline milestones and financing cadence rather than recurring revenue. Financial health depends on available cash and access to capital; near‑term funding needs could lead to dilution absent partnership or milestone inflows. Upside hinges on positive clinical readouts, corporate partnerships, or M&A interest, while downside is concentrated in trial failure, regulatory delays, and broader sector de‑risking. Given limited social/EDGAR visibility and selective sector flows, the share is likely to trade on news and liquidity, with modest near‑term downside risk unless new catalysts emerge.

Key factors

  • Early‑stage clinical pipeline with potential upside from readouts or IND/partnering events
  • Limited or no meaningful commercial revenue; valuation driven primarily by binary clinical milestones
  • Balance sheet and cash runway are likely the primary near‑term constraint on operations and strategic flexibility
  • Biotech sector flows are currently selective and consolidation into large‑cap pharma may divert capital away from smaller developers
  • Regulatory and reimbursement environment remains uncertain and can materially affect future commercial prospects
  • Low current social and EDGAR visibility increases sensitivity to news flow and analyst coverage changes
  • Potential for partnership or M&A interest given larger pharma appetite for specialty franchises, which could be a catalyst

Risks

  • Clinical trial failures or negative data that could sharply reduce valuation
  • Need to raise capital leading to dilution or adverse financing terms
  • Regulatory setbacks, longer approval timelines, or unfavorable labeling
  • Commercial execution risk and uncertainty around payer reimbursement if/when products reach market
  • Competitive entrants or superior therapies that reduce addressable market share
  • Low liquidity and higher share price volatility for small‑cap biotech names
  • Macro market risk and sector rotation away from small growth/biotech stocks

See today's live rating, score and targets

Members see the live hourly rating for TYRA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.